Management of DE With IPL in Combination With DQS

Intense pulsed light (IPL) has been reported to improve signs and symptoms of dry eye (DE). Additionally, meibomian gland secretion of lipids has been observed to improve through the use of IPL. Diquafosol ophthalmic solution (DQS) stimulates P2Y2 receptors on the ocular surface, which enhances mucin secretion from goblet cells. Therefore, tear film stability and hydration of the ocular surface can be achieved independent from lacrimal glands function. The purpose of this prospective study was to evaluate and compare the effects of IPL (IPL group), DQS (DQS group) and IPL in combination with DQS (IPL+ group) in participants with persistent DE. Tear film lipid layer (TFLL), non-invasive breakup time (NITBUT), tear meniscus height (TMH), corneoconjunctival staining score (CS), meibum gland (MG) function, conjunctival hyperemia (RS score), ocular surface disease index (OSDI) will be assessed and compared at baseline, day-14, and day-28.

Inclusion Criteria:Age ≥18 yearsThe presence of at most one symptom including burning, foreign body sensation, itching or eye fatigue for 3 monthsOSDI score ≥ 13 and TBUT <5 s or NIBUT < 10sAble and willing to comply with the treatment/follow-up scheduleExclusion Criteria:A recent history (past 30 days) of topical ophthalmic medication use, including antibiotics, steroids, non-steroidal anti-inflammatory drugs, or required the chronic use of topical ophthalmic medicationsEyelids or intraocular tumors that should not put pressureActive allergy or infection or inflammatory disease that may have prevented the subjects from completing the study at the ocular surfaceAny structural change in lacrimal passageGlaucomaDiabetes or other systemic, dermatologic, or neurologic diseases that affect the health of ocular surfaceUse of any systemic anti-inflammatory drugs or medication that may interfere with tear production, such as antianxiety, antidepressive, and antihistamine medications within 3 months